Marksans Pharma Ltd
Marksans Pharma Q2 FY26: Capex ₹100 Cr
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #66 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Marksans Pharma Ltd Q2 FY26 key numbers
- Revenue
- The US market opportunity for private label OTC is several billion dollars; Marksans is among the top four players but far behind the market leaders.
As stated in Marksans Pharma Ltd's Q2 FY26 earnings call transcript · published 3 Aug 2026. Reported figures, not investment advice.
The short version
The US business is expected to remain a major growth driver, with potential to double revenue in 4-5 years, aiming for around $300 million in 3 years, though geopolitical risks cause some caution. EBITDA margin expected to settle around 19% to 20% range in FY'26, with potential to be slightly better; north of 20% possible but 19%-20% is a safe assumption. - Operating leverage will improve as revenue grows, but initial investments in new markets and infrastructure may increase costs temporarily. - Revenue target to reach Rs.
From Marksans Pharma Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The US business is expected to remain a major growth driver, with potential to double revenue in 4-5 years, aiming for around $300 million in 3 years, though geopolitical risks cause some caution.
- The US market opportunity for private label OTC is several billion dollars; Marksans is among the top four players but far behind the market leaders.
- Europe, especially Germany and four other key countries, is targeted for organic growth starting in 2026, with operations expected to scale in the second half of 2026.
- UK market expected to double revenue within 5-7 years with new product launches and improving pricing environment.
- CAPEX planned in 2026 (~Rs. 100 crores) to increase tablet capacity from 700-800 million to 1.2-1.3 billion tablets per month and triple soft gel capacity, enabling revenue growth beyond Rs. 4,000 crores.
2 more points from Marksans Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Marksans Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planned CAPEX of around ₹100 crores in 2026 to expand tablet capacity at the old Goa plant from 700-800 million to 1.2-1.3 billion tablets per month, also tripling soft gel capacity.
- Expansion focused on acquiring adjacent land and constructing new blocks with shared infrastructure to achieve operating leverage.
- Investment targeted to handle revenue growth beyond ₹4,000 crores and enable scaling towards ₹5,000 crores in the longer term.
- Organic expansion in Europe, especially Germany, with operations starting in FY'26 including hiring employees and infrastructure setup.
- Active pursuit of smaller M&A opportunities across Europe planned for 2026 to complement organic growth.
2 more points from Marksans Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Marksans Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current U.S. order book stands between $225 to $230 million, indicating a strong position. (Page 4)
- The company has ample manufacturing capacity, especially at the Teva plant, currently under 30% utilized, allowing for expansion without immediate capacity constraints. (Page 7)
- Despite tariff uncertainties over the last six months, clarity has recently emerged, improving client confidence and order momentum. (Pages 7, 10)
2 more points from Marksans Pharma Ltd's call on order book
Create a free account to keep reading this call
Marksans Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹856 Cr, net profit ₹149 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Marksans Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Marksans Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Marksans Pharma Ltd Q2 FY26 results?
The US business is expected to remain a major growth driver, with potential to double revenue in 4-5 years, aiming for around $300 million in 3 years, though geopolitical risks cause some caution. EBITDA margin expected to settle around 19% to 20% range in FY'26, with potential to be slightly better; north of 20% possible but 19%-20% is a safe assumption. - Operating leverage will improve as revenue grows, but initial investments in new markets and infrastructure may increase costs temporarily. - Revenue target to reach Rs.
What is Marksans Pharma Ltd share price analysis?
Marksans Pharma Ltd currently shows a neutral. The stock trades at a P/E of 29.4 with a market cap of ₹12,265 Cr. Investors should review the full earnings analysis for detailed insights.
Is Marksans Pharma Ltd planning capital expenditure?
Planned CAPEX of around ₹100 crores in 2026 to expand tablet capacity at the old Goa plant from 700-800 million to 1.2-1.3 billion tablets per month, also tripling soft gel capacity.
Keep Marksans Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.